Compare DLHC & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLHC | SERA |
|---|---|---|
| Founded | 1969 | 2008 |
| Country | United States | United States |
| Employees | 2300 | N/A |
| Industry | Business Services | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.8M | 79.5M |
| IPO Year | 2012 | 2021 |
| Metric | DLHC | SERA |
|---|---|---|
| Price | $5.71 | $2.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.4K | ★ 24.1K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.32 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $41,923,000.00 | $81,000.00 |
| Revenue This Year | N/A | $554.81 |
| Revenue Next Year | $0.05 | $517.27 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 2.57 | ★ 5.19 |
| 52 Week Low | $3.41 | $1.37 |
| 52 Week High | $8.09 | $4.09 |
| Indicator | DLHC | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 49.36 | 51.21 |
| Support Level | $5.55 | $1.72 |
| Resistance Level | $6.05 | $2.41 |
| Average True Range (ATR) | 0.26 | 0.17 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 49.58 | 60.12 |
DLH Holdings Corp delivers health and readiness solutions for federal government customers through digital transformation and cyber security, science research and development, and systems engineering and integration. It provides technology-enabled business process, program management, and digital transformation solutions to U.S. government agencies, focusing on large-scale, technology-powered health and defense initiatives for agencies including HHS, VA, DoD, and their sub-agencies. Its revenues come from technology-enabled business process outsourcing, program management solutions, and public health research and analytics under time-and-materials, cost-reimbursable, and firm-fixed-price contracts.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.